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METHODS 
The data presented in this paper are based on a Medline search of
the literature from 1966 to May 2001 and a Cancerlit search from
1983 to May 2001. Both searches were performed on Ovid
Medline. The search strategy combined the following four
concepts using available MeSH terms: 
Concept 1 (exp pregnancy or exp pregnancy complication); and 
Concept 2 (exp developmental disabilites or exp ‘behaviour and
behaviour mechanisms’ or exp cognition disorders); and 
Concept 3 (exp antibiotics, anthracycline or exp antibiotics, anti-
neoplastic, exp antineoplastic agents, or antineoplastic agents,
combined or exp antineoplastic agents, hormonal or exp anti-
neoplastic and immunosuppressive agents or exp radioisotopes
or exp anesthetics or prednisone or bromocriptine or glucocor-
ticoids or exp estrogens); and 
Concept 4 (exp neoplasms). 
The search was not limited to specific languages, age groups or
human studies. The studies were reviewed for details on fetal brain
development evidenced postnatally by different physical, neuro-
logical and neurodevelopmental tests. 
MATERNAL CANCER 
Whether an association of maternal cancer with pregnancy has an
undesirable effect on neurodevelopment in later childhood remains
largely unknown. Metastasis to the placenta and/or fetus is very rare
(Gililland and Weinstein, 1983; Potter, 1970). Melanoma is the most
frequent of the few malignancies that do metastasize to the placenta
and fetus (Gililland et al, 1983). Live born children exposed to such
malignancies tend to die within a 1 day to 10 month period.
Comprehensive reports about physical and mental health of the
surviving children are not available. 
The cancer patient has an increased tendency to experience
febrile illnesses due to infections and/or as a result of the tumour
itself. The relationship between hyperthermia, fetal brain develop-
ment, and the incidence of impairment in human children has not
been fully addressed. However, many human studies do support the
hypothesis that maternal fever in early pregnancy is associated with
an increased risk of NTDs and microphthalmia (Chambers et al,
1998; Miller et al, 1978; Layde et al, 1980; Clarren et al, 1979).
Malignancies may also be associated with maternal malnutrition
and adverse neonatal outcome (Metcoff et al, 1981; Brown et al,
1981). Although animal studies have shown that severe maternal
undernutrition can result in stillbirths and increased perinatal
mortality, retrospective analyses of human data obtained during
historical periods of starvation have shown little or no adverse
fetal effects (Pritchard et al, 1985). Several studies have suggested
that severe ketoacidosis due to dehydration or severe weight loss
may pose an additional risk to the developing fetus (Naeye et al,
1981). On the other hand, analysis of males at age 19 born to
mothers starved during pregnancy failed to document any differ-
ences in IQ score between these boys and the general male popula-
tion (Stein et al, 1972). 
SURGERY 
Surgical interventions may be required for the evaluation and
treatment of malignancies diagnosed in pregnancy. Each year
about 0.5% to 2% of pregnant women in North America undergo
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mately 7000 to 30 000 of these women are in the first trimester of
pregnancy (Sylvester et al, 1994), a critical time for the develop-
ment of the central nervous system (CNS) (Webster et al, 1988).
This is also the time period when the woman may not be aware of
her pregnancy. Some women are occupationally exposed to anaes-
thetics throughout gestation. Little is known about neurodevelop-
mental outcomes due to exposure in either surgical or occupational
conditions. During surgery the fetus is exposed to a potential risk
from the effects of anaesthetic agents in addition to complications
that may arise during or as a result of maternal surgery. Surgery in
pregnancy is often associated with hypotension, hypoxia, coagula-
tion, metabolic disturbances, and decreased utero-placental perfu-
sion secondary to prolonged maintenance in the supine position.
Each of these conditions can threaten fetal well being (Doll et al,
1988). 
There are studies that establish the safety of the most commonly
used anaesthetic agents during pregnancy, including nitrous oxide,
enflurane, barbiturates, and narcotics (Schardein, 1985). Friedman
(1988) reviewed possible teratogenic effects of general anaesthetics,
local anaesthetics, and occupational exposure to anaesthetic gases.
He concluded that data available on these agents do not suggest a
major teratogenic risk in humans.
Kallen and Mazze (1990), in a case control study, assessed the
pregnancy outcome of 2252 infants born to women who had
surgery in the first trimester. Six neonates (expected number = 2.5)
had a definite diagnosis of neural tube defect (NTD). Five of these
6 mothers were operated on in the fourth and fifth weeks of gesta-
tion, the window of exposure in which NTDs may take place.
Sylvester (1994), in a large population-based case-controlled
study, evaluated whether exposure to maternal general anaesthesia
is associated with an increase in fetal CNS abnormalities. Twelve
of 694 mothers with infants who had CNS defects reported having
first trimester surgery with anaesthesia. Thirty-four of the 2984
controls were exposed to general anaesthesia at the same time of
gestation (OR = 1.7, 95% CI-0.8,3.3). The strongest association
was observed between exposure to anaesthesia and hydrocephalus,
as well as eye defects. Although available studies have indicated
that the CNS is the most sensitive organ to surgical and anaesthetic
damage, none of the studies have addressed later childhood
neurodevelopment or cognition. Functional CNS abnormalities
may exist even when structural abnormalities are not observed. 
MEDICATIONS 
Cytotoxic drugs 
The common denominator of anti-cancer drugs is the ability to
affect cell division adversely. Therefore, the same qualities that
make those compounds desirable for cancer therapy, may also
render them detrimental to the developing embryo. The dose of
medication and time of exposure are critical during embryogenesis
when susceptibility to teratogenic agents is high (Webster et al,
1988). A number of studies focused on congenital malformations
at the time of delivery, and concluded that when chemotherapy is
administered to women before conception or after the first
trimester, in the majority of cases normal births are experienced
(Harada, 1978; Gililland and Weinstein, 1983; Doll et al, 1988;
Cantini and Yanes, 1984). These conclusions may not apply to the
CNS, which develops throughout gestation and postnatally.
Xenobiotics, including some heavy metals, ethanol and cocaine,
are known to adversely affect CNS development during the second
and third trimester (Koren et al, 1994; Harada, 1978). 
Cognitive and behavioural functioning of children exposed in
utero to chemotherapy at different periods of gestation remain
largely undefined. Available data are based on small series and
case reports. These reports suggest that gross and mental develop-
ment of children exposed in utero to chemotherapy appears to be
normal, but most authors did not conduct formal motor, cognitive
and behavioural tests. As a result, they may have missed the
opportunity to detect more subtle neurodevelopmental abnormali-
ties. In case reports of women who were treated with a variety of
chemotherapeutic agents and the developmental outcome was
reported, the infants presented normal growth and developmental
milestones at 3–21 months following delivery (Odom et al, 1990).
However, Reynoso (1987) and Cantini (1984) reported 2 children
with mental and or growth retardation born to mothers treated in
pregnancy for acute leukaemia. 
Presented below are the data concerning late effects of
chemotherapy on children’s neurodevelopment (Table 1). Blatt
et al (1980) assessed retrospectively pregnancy outcome in
patients who received aggressive moderate to high-dose combina-
tion chemotherapy for various oncologic diseases. Two patients
conceived during treatment, which was continued for the first 2
months of gestation, and two other women started chemotherapy
in the second and third trimester respectively. At the time of eval-
uation, the offspring ranged in age from several days to 12 years.
Development was evaluated using the Denver Developmental
Screening Test, and school performance was ascertained by
history. Growth and development as well as school performance
appeared to be normal in these children. 
The peak incidence of Hodgkin’s disease occurs during the
reproductive years. Therefore, it is not surprising that there have
been more reports on long-term follow-up for Hodgkin’s disease
than for other malignancies. Baisogolov and Shishkin (1985)
reported on the pregnancy outcome of 78 retrospectively collected
patients with Hodgkin’s disease who delivered 89 children. The
data were collected from the parents by local paediatricians.
Twenty-one women conceived while undergoing chemotherapy.
The psychomotor development of the case children was not
different from that of the controls (children of healthy mothers).
Seventeen out of 19 school-aged children were considered as
‘good’ or ‘excellent’ students. Twelve of these children were good
in mathematics, 6 were in advanced programs to study foreign
languages, 4 studied music, and 10 were good in sports. Another 7
children were gifted in other areas. A study conducted in Poland
reported on the outcome of 20 pregnancies in 16 women with
Hodgkin’s disease (Balcewicz-Sablinska et al, 1990). In three
pregnancies, cytostatic treatment was given after the first
trimester. The course and labour of the observed pregnancies were
normal. All babies were born healthy and were followed for a
period of 6 years. The development of these children was reported
to be normal, although formal psychological assessments were not
performed. 
The pregnancy outcome of women with haematologic malig-
nancies, screened between 1970 and 1986, was presented by
Aviles et al (1991). Forty-three children were born to 43 mothers
who were treated with chemotherapy for non-Hodgkin’s
lymphoma, Hodgkin’s disease, acute leukaemia, or chronic granu-
locytic leukaemia. Nineteen women received chemotherapy
during the first trimester. The children’s ages ranged from 3 to 19
years in 1989 at the time of testing. They were evaluated by
1612 I Nulman et al 
British Journal of Cancer (2001) 85(11), 1611–1618 © 2001 Cancer Research CampaignM
a
t
e
r
n
a
l
 
m
a
l
i
g
n
a
n
c
y
:
 
c
h
i
l
d
’
s
 
o
u
t
c
o
m
e
1
6
1
3
B
r
i
t
i
s
h
 
J
o
u
r
n
a
l
 
o
f
 
C
a
n
c
e
r
 
(
2
0
0
1
)
 
8
5
(
1
1
)
,
 
1
6
1
1
–
1
6
1
8
©
2
0
0
1
 
C
a
n
c
e
r
 
R
e
s
e
a
r
c
h
 
C
a
m
p
a
i
g
n
Table 1 In utero exposure to chemotherapeutic agents 
Indication Authors Time of  Study Sample Age 
exposure in design  size assessed Medications Tests Results
pregnancy n = 111 
Different forms Blatt et al, 1980  Preconceptionally Retrospective 4 1 month to 12 Combined Denver Developmental Normal development and 
of malignancies or 1st trimester years old chemotherapy Screening Test. School  school performance 
reports
Hodgkin’s Baisogolov and – Retrospective  19 1 to 14 years Combined Parent and school  Normal development 
disease Shishkin, 1985 old  chemotherapy reports
Hodgkin’s Balcewicz- 1st trimester  Retrospective 3 Up to age 6 MOPP No formal testing Normal development 
disease Sablinska et al,
1990
Hodgkin’s Aviles et al, 1st and 2nd  Retrospective, 15 3 to 17 years MOPP, ABVD  Wechsler and Bender- Not different from 
disease 1991 trimesters controlled Gestalt cognitive tests. controls 
School report
Haematological Aviles et al, 1st trimester,  Retrospective, 43 3 to 19 years Combination  Wechsler and Bender- Not different from 
malignacies 1991 2nd and 3rd  controlled chemotherapy Gestalt cognitive tests. controls 
trimester School report
Acute leukaemia Aviles et al, 1st trimester or  Retrospective, 17 4 to 22 years Combination  Wechsler and Bender- Not different from 
1988 sometime controlled chemotherapy Gestalt cognitive tests. controls 
during School reports
pregnancy
Rheumatic Kozlowsky  1st trimester  Retrospective 5 3.7 to 16.7 Low-dose  Parent reports Normal development 
disease et al, 1990 years methotrexate
Occupational Medkova 1991 Preconceptionally  Retrospective, 5 – Low dose cytostatics  No formal testing Normal development 
exposure and/or during controlled
pregnancyphysical and neurological examination in a ‘blinded’ manner.
Evaluation of the children’s school performance was obtained
from their teachers. The Wechsler and Bender-Gestalt tests were
administered to the children according to their ages, and the results
were compared with those of 25 children of similar age and socio-
economic class. The children in the study group were not different
from their controls in any of the measured tests. 
Leukaemia occurs in approximately one out of 100 000 preg-
nancies (Caligiuri and Mayer, 1989). Aviles and Niz (1988) exam-
ined 17 offspring of patients with acute leukaemia treated during
pregnancy. Chemotherapy was given during the pregnancy in each
case, including 11 cases during the first trimester. The treatment of
acute leukaemia was not modified due to the pregnancy and these
patients received at least 80% of the planned dose. Neurological,
intellectual and visual-motor-perceptual assessments were
performed on the offspring (who ranged in ages between 4 to 22
years), their siblings, and unrelated controls. All children were
given the Wechsler or the Bender–Gestalt test according to their
age. No differences were detected between the groups on any of
the tests. Kozlowski et al (1990) reviewed retrospectively the
outcome of first-trimester exposure to low-dose methotrexate in
eight patients with rheumatic disease. The duration of treatment
ranged from 2 to 20 weeks of gestation. The women were given 7.5
to 10 mg methotrexate weekly. Five full-term live babies were
born with a mean follow-up age of 11.5 years (range 3.7–16.7
years). All children reached normal growth and neurodevelopment.
None of the children had learning disabilities. One child with
speech impairment improved after speech therapy. Unfortunately,
the methods of mental assessments were not reported. 
The outcome of occupational chemotherapy exposure during
pregnancy was addressed by Medkova (1991). The author
reported on the pregnancy outcome and neurodevelopment of
health personnel’s children exposed to small doses of cytostatic
medications. Sixty-one children were born to the healthcare
workers on the oncology unit. In this group, exposure to antineo-
plastic agents was proven in five mothers and five fathers.
Attention was paid to the children’s physical development and
possible incidence of dyslexia or dysgraphia. No abnormalities in
these areas were found. Formal cognitive tests and statistical
comparisons were not reported. 
In summary, the data presented regarding late effects of
chemotherapy on children’s neurodevelopment are incomplete and
are hampered by a lack of population-based, well designed studies.
It is important to note that the paucity of neurobehavioural and
cognitive studies in older children is due to limited late follow-up.
The majority of available reports have focused on immediate
maternal and fetal pregnancy outcomes, not considering later
neurodevelopment as a primary end point, thus using a cross-
sectional rather than longitudinal approach. The studies which did
address long-term neurodevelopmental aspects typically used
retrospective design in order to recruit a sufficient number of
cases. Notwithstanding the limitations, these studies are very
important as they represent the only existing source of information
on the neurodevelopmental outcome of in utero exposure to cyto-
toxic therapy. The general impression, based on these reports, is
that chemotherapy does not have a major impact on later child
neurodevelopment. Methodologically, retrospective studies tend to
show more adverse outcome than prospective studies, due to
reporting bias (e.g.: parents of children with adverse outcome are
more likely to report than those with normal outcome). Hence,
negative retrospective studies are reassuring. With the increased
use of cancer medications in nonmalignant conditions (e.g.: trans-
plant, collagen diseases), it may be possible to recruit larger
numbers of children for prospective, longitudinal studies and
delineate abnormal outcomes induced by the malignancy itself. 
Glucocorticoids 
Glucocorticoids are part of the treatment protocol for many malig-
nancies. They are also used as immunosupressive treatment in organ
transplantation and for fetal lung maturation when preterm delivery is
suspected. Most comprehensive studies on the neurodevelopmental
effects of glucocorticoids were done in late pregnancy. Animal
studies indicate that corticosteroids are associated with cognitive and
behavioural abnormalities when administered during pregnancy. This
has raised concerns about their use in humans (Trautman et al, 1995;
Meaney et al, 1982; Angelucci et al, 1985). Table 2 presents the long-
term effects of glucocorticoids used in gestation. 
A prospective pilot study that investigated the long-term
neurodevelopmental effects of prenatal exposure to dexametha-
sone (DEX) was conducted by Trautman et al (1995). The authors
followed 26 children (ranging in age from 6 months to 5.5 years)
whose mothers took DEX during pregnancy from weeks 1 to 21.
The mothers took DEX for 2–29 weeks for the treatment of fetal
risk for congenital adrenal hyperplasia (CAH). The offspring were
compared with 14 children who were also at risk for CAH, but had
not been exposed to DEX. The authors attempted to separate the
effects of maternal disease by controlling for the same medical
condition without treatment. The results indicated that DEX-
exposed children were less likely to be cognitively delayed on a
comprehension-conceptualization measure of development and
that DEX-exposed 2- to 3-year-old children (n = 14) displayed
more internalizing behaviour than unexposed children of the same
age (n = 4). DEX-exposed children also exhibited a tendency to
show higher avoidance behaviour and to be more shy and
emotional and less sociable than unexposed children. No other
significant differences were reported. 
Pregnancy outcome and long-term follow-up with DEX used as
an immunosuppressive agent taken throughout pregnancy for the
treatment of lupus erythematosus (21 children) and heart trans-
plant patients (29 children) were reported (Tincani et al, 1992;
Wagoner et al, 1993). The authors indicated that the offspring were
doing well at follow-up, but no formal cognitive or behavioural
tests were conducted. 
The literature on exposure to DEX in late pregnancy suggests
that there are no significant cognitive differences between exposed
and non-exposed children (MacArthur et al, 1982; Veszelovsky et al.,
1981; Collaborative Group on Antenatal Steroid Therapy, 1984). The
Collaborative Group on Antenatal Steroid Therapy (1984) was a
prospective, randomized, placebo controlled, double-blinded
study on the use of antenatal DEX for the prevention of respiratory
distress syndrome in infants. The authors evaluated 200 children at
9, 18, and 36 months of age. The Bayley Scales and McCarthy
Scales of Children’s Abilities were used to assess cognitive and
motor development. The results indicated that there were no
significant differences in head circumference, cognitive, develop-
mental or neurologic functioning between the placebo and the
steroid treatment groups. The authors concluded that there were no
detectable effects within the first 3 years of life in children who
were exposed antenatally to DEX. 
MacArthur et al (1982) conducted a double-blind, controlled
study investigating the cognitive and psychosocial development of
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Table 2 Children exposed in utero to glucocorticoids 
Indication Author Time of  Study Sample Age Substance Duration of Tests  Results 
exposure in design size  assessed substance
pregnancy n = 540 use
Lung maturation Veszelovszky  3rd  Retrospective, 125 12–36 Dexamethasone  Neurological and No difference from 
**in Hungarian et al, 1981 trimester controlled months psychological the control group 
Fetal lung MacArthur 3rd  Prospective, 139 Age 4 Betamethasone Stanford-Binet Intelligence No difference from 
maturation et al, 1981 and trimester controlled  and 6 Scale, Frostig Visual  the control group 
1982 Perception Test, Vineland
Social Maturity Scale, Illinois
Test of Psycholinguistic
Abilities, Peabody Vocabulary
Test, Raven’s Matrices,
Bender-Gestalt Test
Fetal lung Collaborative 3rd  Prospective, 200 36 Dexamethasone Bayley Scales, McCarthy No difference from 
maturation Group on trimester randomized,  months Scales the control group 
Antenatal placebo
Steroid Therapy controlled,
(1984) double-blind
Fetal lung NIH Consensus 3rd Analysis of up to age Corticosteroids No increased risk of long- 
maturation Conference, trimester available data 12 term neurodevelopmental 
1995 impairment 
Maternal SLE Tincani et al, Throughout  Prospective 21 1–85 Fluocortolone plus  No formal tests No long-term 
1992 pregnancy months aspirin  and consequences 
azathioprine (if 
needed)
Maternal heart Wagoner et al, During  Prospective 29 3 months Corticosteroids plus  No formal tests All children reported  
transplants 1993 pregnancy to 6.5  other to be in good health 
years immunosuppresives 
Fetal congenital Trautman et al, Started  Porspective, 26 6 months Dexamethasone  2–29 weeks Denver Developmental More shy, emotional, less 
adrenal 1995 from week controlled pilot to 5.5 Questionnaire, Minnesota  sociable, and a trend for 
hyperplasia 1 to 21 study years  Child Development Inventory, greater avoidance than 
weeks of Child Behaviour Checklist, control group. No 
gestation Temperament Questionnaire, differences in cognitive 
EAS Temperament Survey abilities. children whose mothers were treated antenatally with betametha-
sone during preterm labour. A total of 250 children, 139 in the
betamethasone group and 111 in the control group, were studied
through to age 7. The authors used well-established measures of
cognitive, academic, and psychosocial development. Their results
suggested that there were no significant differences in the cogni-
tive or psychosocial development between the two groups. 
The NIH Consensus Conference in 1994 (Anonymous, 1995)
summarized data on the effects of corticosteroids for fetal matura-
tion and perinatal outcomes. The results from available studies did
not indicate any evidence of adverse long-term outcomes associ-
ated with the use of single doses of glucocorticoids for lung matu-
ration in the areas of motor, cognitive, language, memory,
concentration, or scholastic achievement skills. There is however
evidence that repeated doses, similar to what is encountered in
cancer chemotherapy are associated with microcephaly and low
birth weight. 
The results of a prospective control study by French et al (1999)
point to a reduction in head circumference when repeated courses
of corticosteroids were given in late pregnancy. Although smaller
head circumference may be associated with impaired cognitive
outcome, the investigator did not report cognitive impairment. 
In conclusion, although the literature on the impact of cortico-
steroids administration in pregnancy on fetal development is
reassuring, more information is required on long-term effects of
these substances on the CNS development. 
Bromocriptine 
Bromocriptine is an alkaloid that functions as a dopamine receptor
agonist suppressing prolactine production and is the treatment of
choice for pituitary tumours during pregnancy. Pregnancy outcome
and children’s functioning in long-term follow-up (up to age 9
years) in hundreds of children exposed in utero to bromocriptine
were reported (Turkalj et al, 1982; Konopka et al, 1983; Nader,
1990) with no significant findings. However, no reports of formal
tests of cognitive and behavioural functioning are available. 
RADIATION 
Radiation is widely used in the diagnosis and treatment of malig-
nancies. Based on live birth rate statistics in the US, about 33 000
women each year are exposed to diagnostic abdominal radiation in
early pregnancy (US Department of Health and Human Services,
1976). The developing embryo and fetus are extremely sensitive to
ionizing radiation (Brent, 1980). Fetal structures exhibit various
susceptibilities to ionizing radiation and the human brain seems to
be the most sensitive organ. The CNS maintains its sensitivity to
radiation throughout gestation and into the neonatal period, when
morphological changes can still be observed. Ionizing radiation is
a CNS teratogen and is a recognized cause of mental retardation. It
has been suggested to be a more serious fetal risk than maternal
cancer following in utero exposure (Hoel, 1987). The lowest dose
of radiation that produces significant behavioural changes postna-
tally at any gestational day is 0.2 Gy (Schull et al, 1990). 
Although radiation is one of the most studied environmental
hazards in animal species, there are very few human studies avail-
able. Brent (1980) hypothesized that a radiation dose as low as 50
rad (0.5 Gy) in humans may be harmful to the fetus, especially to
its CNS. Dekaban (1968), in a retrospective analysis, reported that
22 infants who were exposed to radiation in the third to twentieth
week of gestation for treatment purposes, were microcephalic
and/or mentally retarded. Woo et al (1992) reported results of 16
women treated for nodular sclerosing Hodgkin’s disease. Seven
women were treated during the first trimester, 10 in the second,
and 8 in the third. Sixteen women received 35–40 Gy for supra-
diaphragmatic nodes. The uterus was shielded by a 4 to 5 hold-value
layer of lead. The estimated dose to the mid-fetus ranged from 1.4 to
5.5 cGY for 6 MV photons and 10 to 13.6 cGY for cobalt 60. All 16
patients subsequently delivered full-term normal infants, who, at the
time of assessment, were found to be physically and mentally
normal. Formal cognitive tests were not reported. 
The experience at Hiroshima and Nagasaki is the most
commonly sited source of knowledge considering long-term
effects of radiation on the human embryo and fetus. These popula-
tion based studies addressed relationships between dose of radia-
tion and gestational age. Analysis of the data of survivors of the
atomic bombings in Japan using refined estimates of the absorbed
fetal dose demonstrated that the highest risk of brain damage
occurred at 8–15 weeks of gestational age (Otake and Schull,
1984). These data were consistent with a linear dose-response
model, which did not indicate the existence of a threshold level. 
In contrast, the data collected for in utero exposures after the
fifteenth week of gestation were not linearly related to dose,
suggesting that a nonlinear model with a threshold dose for radia-
tion effects best fits the data for this period of gestation. Radiation
exposure before the eighth week of gestation and after the twenty-
fifth week was not associated with an increased risk of mental
retardation. Yoshimaru et al (1991) assessed school performance
of prenatally exposed survivors of the atomic bombings using the
DS86 dosimetry system and found that damage to the fetus
exposed at 16–25 weeks after fertilization appeared similar to that
seen in the 8–15 week group. Other studies of this population also
suggest that radiation exposure in utero may affect intelligence test
scores, with the greatest sensitivity during the eighth to fifteenth
week of gestation (Mettler et al, 1985). One estimate of the dose-
response relationship was a 20-point loss of IQ for each additional
1 Gy of exposure. The relationship between dose and intelligence
test scores is not yet well-established, and the findings have to be
refined to a demonstrable level of statistical significance or clin-
ical relevance (Mettler et al, 1985). Jensh and Brent (1987)
demonstrated a downward shift in the Gaussian distribution of IQ
with an estimated probability coefficient indicating a loss of 30 IQ
points per 1 Gy fetal dose at 8–15 weeks after conception. A
similar, but smaller shift to lower intelligence was detectable
following exposure at 6–25 weeks of gestation, but not at other
periods of pregnancy. Several reports did not find mental retarda-
tion in 19 children exposed to 0.015 and 0.1 Gy and among 1458
children exposed to low diagnostic doses of radiation (Meyer and
Tonascia, 1981). However, behavioural tests were not performed
and these results should be interpreted with caution because of
methodological limitations of the study design. Conversely, in a
case control study, Granoth (1979) assessed the association of
diagnostic X-ray examinations with the occurrence of CNS defects
and found a significant increase in anencephaly, hydrocephaly, and
microcephaly when the study group is compared with matched
control infants. The cognitive and behavioural effects of low-dose
prenatal diagnostic radiation has not been elucidated. As well, it is
unknown whether there are behavioural sequelae due to exposure
to radiation in the area of the electromagnetic spectrum. To date it
is believed that fetal exposure to less than 0.05 Gy does not
increase the teratogenic risk (Jensh and Brent, 1986). 
1616 I Nulman et al 
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for a teratogen (Vorhees, 1986). Being neurotropic, radiation is
capable of producing behavioural teratogenic effects that are
demonstrable at doses below those causing obvious structural
malformations (Vorhees, 1986). 
In addition to the classic triad produced by a teratogenic
substance, ionizing radiation was observed to cause obvious
behavioural alternations in animals. As suggested by Jensh and
Brent (1986) the inseparable radiation teratogenic effect on
behaviour must be added to the triad thus creating a ‘tetrad’. 
CONCLUSION 
Malignancy poses a difficult challenge to both patients and physi-
cians, creating a conflict between optimal maternal therapy and
fetal well-being. However, most malignant conditions are not
absolute contraindications for pregnancy. Unfortunately, neurode-
velopmental and behavioural effects, both important parts of the
teratogenic spectrum regarding drug or treatment safety, have been
only sparsely addressed. Mental health effects, which act as strong
predictors of a child’s quality of life, merit closer attention, as does
the cognitive and behavioural effects of these drugs. At the present
time little is known on the long term mental health effects in young
children exposed in utero to treatment for maternal cancer.
However, existing studies on cancer chemotherapy beyond the
first trimester have failed to show neurotoxicity. In contrast,
repeated doses of corticosteroids and radiation are definitely
teratogenic. Further research is required to assess the behavioural
teratology of cancer and its management. 
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